Dupilumab for hair regrowth in children with alopecia areata
Dupilumab in the Treatment of Pediatric Alopecia Areata
This project gives dupilumab to children and teens with widespread alopecia areata, especially those with allergies or high IgE, to help their hair grow back.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11322610 on NIH RePORTER |
What this research studies
You or your child would receive regular dupilumab injections and be followed over time to track hair regrowth and side effects. The study focuses on pediatric patients with extensive scalp hair loss and often an atopic history like eczema or high IgE. Doctors will take photos, clinical hair counts, and small scalp samples to study immune signals linked to response. The team is building on adult results that showed hair regrowth with dupilumab to see if similar benefit occurs in younger patients.
Who could benefit from this research
Good fit: Children and adolescents with extensive (≥50%) scalp hair loss from alopecia areata, particularly those with atopic dermatitis, allergies, or high blood IgE levels, would be ideal candidates.
Not a fit: Patients without an atopic background or low IgE, those with very limited scalp involvement, or individuals who cannot receive dupilumab may be less likely to benefit.
Why it matters
Potential benefit: If successful, this could help children with extensive alopecia areata regrow scalp hair and provide a safer targeted option for long-term treatment.
How similar studies have performed: A prior clinical trial in adults with alopecia areata reported significant hair regrowth and molecular changes with dupilumab, so this pediatric effort builds on promising adult results.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Guttman, Emma — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guttman, Emma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.